A scene-by-scene explanation of satiety signaling, slower gastric emptying, insulin response, and why patients describe the sudden quieting of food noise.
Open interactiveGLP-1 coverage is tightening in 2026, not disappearing. Learn why costs are driving stricter prior authorization and diabetes-vs-weight-loss distinctions, and what questions to ask your doctor, HR team, or insurer to protect your access.
Read moreGive someone arriving cold a grounded, jargon-free answer to what GLP-1 medications are, who they are for, and what they actually do in the body.
Read moreA plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreAcross GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 coverage is tightening in 2026, not disappearing. Learn why costs are driving stricter prior authorization and diabetes-vs-weight-loss distinctions, and what questions to ask your doctor, HR team, or insurer to protect your access.
Full analysisWe track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Started publishing Oct 2024
Medicine Uncovered is broader medical journalism first and a GLP-1 source second. It is worth tracking when obesity treatment starts crossing into larger reporting questions around medicine, health systems, and public understanding. This is a better fit for readers who want occasional strong reporting than for people looking for a dedicated obesity beat.
Started publishing Jan 2023
Jake Goodman’s publication is mostly about mental health and public-facing medicine, not obesity treatment. It still earns a place here because the GLP-1 pieces are accessible, widely shared, and written for readers who want straightforward answers instead of specialist jargon. Think of it as a general-audience crossover source, not a dedicated obesity desk.
Started publishing Sep 2020
Halle Tecco is especially good at explaining how obesity care gets built, sold, reimbursed, and scaled. If you want to understand telehealth GLP-1 companies, payer pressure, startup behavior, and the business logic behind the care models patients keep running into, this is one of the sharper reads in the category. It is less about day-to-day prescribing and more about the machinery around modern obesity treatment.
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.